Systemic Oncological Treatments versus Supportive Care for Patients with Advanced Hepatobiliary Cancers: An Overview of Systematic Reviews
Authors:
- Javier BracchiglioneJBJavier Bracchiglione
- Gerardo Rodríguez-GrijalvaGRGerardo Rodríguez-Grijalva
- Carolina RequeijoCRCarolina Requeijo
- Marilina SanteroMSMarilina Santero
- Josefina SalazarJSJosefina Salazar
- Karla Salas-GamaKSKarla Salas-Gama
- Adriana-Gabriela MeadeAMAdriana-Gabriela Meade
- Alba AntequeraAAAlba Antequera
- Ariadna Auladell-RispauAAAriadna Auladell-Rispau
- María Jesús QuintanaMQMaría Jesús Quintana
- Ivan SolàISIvan Solà
- Gerard UrrútiaGUGerard Urrútia
Open Access
Abstract
Background: The trade-off between systemic oncological treatments (SOTs) and UPSC in patients with primary advanced hepatobiliary cancers (HBCs) is not clear in terms of patient-centred outcomes beyond survival. This overview aims to assess the effectiveness of SOTs (chemotherapy, immunotherapy and targeted/biological therapies) versus UPSC in advanced HBCs. Methods: We searched for systematic reviews (SRs) in PubMed, EMBASE, the Cochrane Library, Epistemonikos and PROSPERO. Two authors assessed eligibility independently and performed data extraction. We estimated the quality of SRs and the overlap of primary studies, performed de novo meta-analyses and assessed the certainty of evidence for each outcome. Results: We included 18 SRs, most of which were of low quality and highly overlapped. For advanced hepatocellular carcinoma, SOTs showed better overall survival (HR = 0.62, 95% CI 0.55–0.77, high certainty for first-line therapy; HR = 0.85, 95% CI 0.79–0.92, moderate certainty for second-line therapy) with higher toxicity (RR = 1.18, 95% CI 0.87–1.60, very low certainty for first-line therapy; RR = 1.58, 95% CI 1.28–1.96, low certainty for second-line therapy). Survival was also better for SOTs in advanced gallbladder cancer. No outcomes beyond survival and toxicity could be meta-analysed. Conclusion: SOTs in advanced HBCs tend to improve survival at the expense of greater toxicity. Future research should inform other patient-important outcomes to guide clinical decision making.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/00034)
- European Regional Development Fund (PI18/00034)
This publication has 84 references indexed in Scilit:
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS StudyJournal of Clinical Oncology, 2013
- A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular CarcinomaThe Oncologist, 2013
- Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled studyJournal of Hepatology, 2012
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- Best Supportive Care Compared With Chemotherapy for Unresectable Gall Bladder Cancer: A Randomized Controlled StudyJournal of Clinical Oncology, 2010
- Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced CancerJAMA, 2009
- Aggressiveness of Cancer Care Near the End of Life: Is It a Quality-of-Care Issue?Journal of Clinical Oncology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJNCI: Journal of the National Cancer Institute, 2008
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008